EW Form 144 Notice: Insider Plans Sale of 2,500 Shares on NYSE

Rhea-AI Filing Summary

Edwards Lifesciences (EW) Form 144 notifies of a proposed sale of 2,500 shares of common stock through Charles Schwab & Co., Inc. with an aggregate market value of $204,865.00. The sale is scheduled to occur approximately on 08/25/2025 on the NYSE. The shares being offered were acquired as equity compensation: 657 shares from RSU/PSU on 05/08/2022, 1,671 shares from a restricted stock lapse on 05/17/2022, and 172 shares from a restricted stock lapse on 05/03/2023. No securities were reported sold in the past three months on this form. The filer certifies compliance with the Rule 144 representation regarding material nonpublic information.

Positive

• Clear compliance with Rule 144 disclosure requirements including broker, exchange, share count, and acquisition details
• Securities originated from equity compensation (RSU/PSU and restricted stock lapse), not from recent open-market purchases

Negative

• Proposed sale of 2,500 shares valued at $204,865 could be viewed negatively by some investors if perceived as insider selling
• Filer identity and post-sale holdings are not disclosed on this form, limiting assessment of insider's remaining exposure

Insights

Securities Analyst

TL;DR Insider intends to sell 2,500 EW shares (approx. $205k) acquired via equity compensation; disclosure appears routine under Rule 144.

The filing shows a proposed disposition executed through Charles Schwab with the sale date set for 08/25/2025. The lots originated from equity compensation events in 2022 and 2023, indicating these are previously granted shares rather than newly purchased open-market buys. The absence of reported sales in the prior three months suggests this notice is not part of an ongoing rapid divestiture pattern. From a disclosure and compliance standpoint, the form fulfils Rule 144 notice requirements by identifying broker, share counts, acquisition dates, and nature of acquisition.

Corporate Governance Specialist

TL;DR The filing is a standard insider sale notice; documentation and representations required by Rule 144 are present.

The details provided—broker name, exchange, share counts, acquisition method, and certification about material nonpublic information—are consistent with standard governance practices for pre-regulation insider sales. The holdings were acquired through RSU/PSU grants and restricted stock lapses, which is common for employees/executives. The filing does not disclose the seller's title or aggregate post-sale holdings, limiting assessment of potential governance implications.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Charles Schwab & Co., Inc. 3000 Schwab Way Westlake TX 76262	2500	204865.00	587100000	08/25/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	05/08/2022	RSU / PSU	EDWARDS LIFESCIENCES CORPORATION			657	05/08/2022	Equity Compensation
Common	05/17/2022	Restricted Stock Lapse	EDWARDS LIFESCIENCES CORPORATION			1671	05/17/2022	Equity Compensation
Common	05/03/2023	Restricted Stock Lapse	EDWARDS LIFESCIENCES CORPORATION			172	05/03/2023	Equity Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filed for Edwards Lifesciences (EW) report?

The form reports a proposed sale of 2,500 common shares via Charles Schwab on the NYSE, with an aggregate market value of $204,865.00, planned for 08/25/2025.

How were the shares being sold acquired?

The shares were acquired as equity compensation: 657 shares from RSU/PSU on 05/08/2022, 1,671 shares from restricted stock lapse on 05/17/2022, and 172 shares from restricted stock lapse on 05/03/2023.

Does the filing show recent sales of EW shares by this person?

No. The Form 144 indicates Nothing to Report for securities sold during the past three months.

Through which broker and exchange will the sale occur?

The sale is to be executed through Charles Schwab & Co., Inc. and listed for sale on the NYSE.

Does the filer assert they possess any material nonpublic information?

By signing the notice, the filer represents they do not know any material adverse nonpublic information about the issuer that has not been publicly disclosed.